Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00814983

Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft

Sponsor: Duke University

Interventions Isolex device from Baxter Naive T-cell Depleted Stem Cell Transplant Stem Cell Transplant No Manipulation

Updated 6 times since 2017 Last updated: Sep 25, 2013 Started: Jul 31, 2007 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

IND approval for naive T-cell depletion not obtained

Other terminated trials from Duke University

See all terminations from Duke University

Other ALL trials with similar outcome

Browse all ALL trials

This PHASE1/PHASE2 trial investigates ALL and ANLL and is currently terminated or withdrawn. Duke University leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1_PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Duke University

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.